-
Sanofi, despite the pandemic, sees early gains from CEO Hudson's strategy — Trump administration to require insurers to cover COVID-19 vaccine — Regeneron/Sanofi's Libtayo gets priority review in NSCLC — See more on our front page news Stay updated with the latest pharma-related coronavirus news on our new pageDismiss Notice
-
Please take our quick survey on how COVID-19 is impacting your job It will only take a minute or two to respond. The survey is confidential, and does not require registration. Thank you in advance for your participation. We will provide regular updates on results as responses accumulate.Dismiss Notice
Recent Posts
-
COVID Face To Face Shut Down?
How soon to everyone being back home across the US? and then more layoffs?
-
Watch out, Merck: FDA grants Regeneron, Sanofi's Libtayo priority review for coveted...
via One month after Regeneron and Sanofi posted impressive data from a phase 3 trial of their PD-1 inhibitor Libtayo in first-line non-small cell lung cancer (NSCLC), the FDA has shifted the drug into the fast lane—possibly offering the companies...
-
Sanofi to Evaluate THOR-707 with Merck's Checkpoint Inhibitor Keytruda
via Sanofi is partnering with Merck to test its THOR-707 compound with Merck’s checkpoint inhibitor Keytruda (pembrolizumab) in solid tumors. THOR-707 is a non-alpha IL-2 candidate that is currently being studied in Phase I trials in solid...
-
Chemocentryx takes a leap of faith with avacopan
via The failure of Inflarx’s IFX-1 had already sown doubts about Chemocentryx’s similarly acting lead project, avacopan, in the skin disease hidradenitis suppurativa. Now it seems Chemocentryx is going to ignore a new red flag: despite the phase...
-
Trump administration to require insurers cover coronavirus vaccines
via The Trump administration will require most private health plans to cover an approved coronavirus vaccine and its administration with no cost-sharing once the shot is recommended by a Centers for Disease Control and Prevention panel. article...
-
AstraZeneca's Fasenra spares asthma patients from steroid use in large trial
via In a single-arm phase 3b trial, Fasenra helped 62% of nearly 600 patients with severe asthma to go on about their lives without oral corticosteroids, AstraZeneca said Thursday. More patients, or 81%, had their daily steroid dose reduced to...
-
Bankruptcy
So true they do ask, and you may want an ethical response because you will be scrutinized
- + Show More
-
General Discussion
Discussion boards of general interest for those in the pharma, biotech, medical device, and related industries
-
Pharma/Biotech Companies
Anonymous discussion boards for pharmaceutical and biotech companies
-
Regional/Metro Area Boards
Discussion and job opportunities by region
-
Lost Civilizations
Anonymous discussion boards for pharma/medical companies that no longer exist due to acquisition or other factors
-
Laboratory/Diagnostic Sales
Anonymous discussion boards for lab sales/diagnostics companies
-
Animal Health Sales
Anonymous discussion boards for animal health companies
-
Medical Equipment/Device Sales
Anonymous discussion boards for medical equipment/device companies
-
PBMs
Anonymous discussion boards for PBMs
-
Pharma/Healthcare Marketing Agencies
Anonymous discussion boards for pharma/healthcare marketing agencies
-
Dental Reps
Anonymous discussion boards for dental health companies
-
Managed Care Specialists
Anonymous discussion boards for managed care specialists
-
Pharma IT
Anonymous discussion boards for pharma IT employees